PTO/SB/05 (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE and to a collection of information unless it displays a valid OMB control number Under the Paperwork Reduction Act of 1995, no persons are required to res

## UTILITY PATENT APPLICATION

an co to re	sporta to a collection	TO Illion later unless it displays a valid ONB control flumb	
Attorney Docket No.		IFM-005CP4CN2	
First Inventor		William G. Tatton	
Title DEPRENYL COMPOUNDS FOR TREATING GLAUCOMA			

TRANSMITTAL	Title	DEPRENYL COMPOUNDS FOR TREATING GLAUCOMA				
(Only for new nonprovisional applications under 37 CFR 1.53(b))	Expre	ess Mail Label No.   EV311018915US				
APPLICATION ELEMENTS See MPEP chapter 600 concerning utility patent application con		ADDRESS TO:  MS Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450				
	7 ] 3 ] 4 ]	7. CD-ROM or CD-R in duplicate, large table or Computer Program (Appendix)  8. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)  a. Computer Readable Form (CRF)  b. Specification Sequence Listing on:  i. CD-ROM or CD-R (2 copies); or ii. Paper  c. Statements verifying identity of above copies  ACCOMPANYING APPLICATION PARTS  9. Assignment Papers (cover sheet & document(s))  10. 37 CFR 3.73(b) Statement (when there is an assignee) Attorney  11. English Translation Document (if applicable)  12. Information Disclosure Statement (IDS)/PTO-1449 Citations  13. Preliminary Amendment  14. X Return Receipt Postcard (MPEP 503) (Should be specifically itemized)  15. Certified Copy of Priority Document(s) (if foreign priority is claimed)  16. Nonpublication Request under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent.  17. Other:				
18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in the first sentence of the specification following the little, or in an Application Data Sheet under 37 CFR 1.76:						
X Continuation Divisional Continuation		10/2/100/				
Prior application information: Examiner Zohreh A. Fay Art Unit: 1614  For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.						
		ONDENCE ADDRESS				
X Customer Number: 00959		OR Correspondence address below				
Name LAHIVE & COCKFIELD, LLP Elizabeth A. Hanley						
Address 28 State Street						
City Boston Stat		MA Zip Code 02109				
	lephone	(617) 227-7400   Fax   (617) 742-4214				
Name (Print/Type) Merideth C Affold		Registration No. (Atterney/Agent) 52,568				
Signature Date October 30, 2003						
•						

Under the Paperwork Reduction Act of 1995, n	U.S. Patent and persons are required to respond to a collection	PTO/SB/22 (08 Approved for use through 7/31/2006. OMB 0651-0 d Trademark Office; U.S. DEPARTMENT OF COMMER on of information unless if displays a valid OMB control num				
PETITION FOR EXTENSION OF						
	In re Application of William	G. Tatton				
	Application Number 10/211007-Conf. #757	Filed				
		11494012, 2002				
	For: DEPRENYL COMPOUI	NDS FOR TREATMENT OF GLAUCOMA				
	Art Unit 1614	Examiner Z. Fay				
This is a request under the provisions identified application.	of 37 CFR 1.136(a) to extend the	e period for filing a reply in the above				
The requested extension and appropriate non-small-entity fee are as follows (check time period desired):						
One month (37 CFR 1.17	\$					
Two months (37 CFR 1.1	\$					
Three months (37 CFR 1	\$ 950.00					
Four months (37 CFR 1.1	\$					
Five months (37 CFR 1.17(a)(5))  *  Applicant claims small entity status. See 37 CFR 1.37. Therefore the five status is a small entity status.						
Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$475.00						
A check in the amount of the fee is enclosed.						
Payment by credit card. Form PTO-2038 is attached.						
The Director has already been authorized to charge fees in this application to a Deposit Account.  The Director is hereby authorized to charge any fees which may be required, or credit any						
overpayment, to Deposit Accou	ınt Number 12-0080	be required, or credit any				
I have enclosed a duplicate copy of this sheet.						
assignee of record	of the entire interest. See 37 CFI	R 3.71				
Statement und	er 37 CFR 3.73(b) is enclosed. (F	Form PTO/SB/96).				
attorney or agent of record. Registration Number  attorney or agent under 37 CFR 1.34(a).						
Registration number	er if acting under 37 CFR 1.34(a)	52,568				
October 30, 2003  Date  October 30, 2003						
(617) 227-7400		Signature  Merideth C. Arnold				
Telephone Number  NOTE: Signatures of all the inventors or assigne	es of record of the entire interest or the	Typed or printed name sentative(s) are required. Submit multiple forms if more				
than one signature is required, see below		seniauve(s) are required. Submit multiple forms if more				
Total of 1	forms are submitted.					
haraby cortify that this						

I hereby certify that this correspondence is being deposited with the U.S. Postar Saprice as Express Mail, Airbill No. EV311018907US, in an envelope addressed to: Commissioner for Patents, P.O. Box 450, Mexandra, VA 22218-1450, of the date shown below.

Dated: October 30, 2003

Signature

Werideth C. Arnold)